{
    "organizations": [],
    "uuid": "c32b5898dd1b8e8f53b0b33e850db11a489b8965",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-opiant-pharmaceuticals-to-record-a/brief-opiant-pharmaceuticals-to-record-about-11-7-million-in-royalty-idUSASB0C4S3",
    "ord_in_thread": 0,
    "title": "BRIEF-Opiant Pharmaceuticals To Record About $11.7 Million In Royalty",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 8 (Reuters) - Opiant Pharmaceuticals Inc:\n* OPIANT PHARMACEUTICALS TO RECORD APPROXIMATELY $11.7 MILLION IN ROYALTY AND MILESTONE PAYMENTS RELATED TO 2017 SALES OF NARCAN® NASAL SPRAY FOR OPIOID OVERDOSE\n* OPIANT PHARMACEUTICALS - ‍WILL RECORD TOTAL OF ABOUT $11.7 MILLION ROYALTY, MILESTONE PAYMENTS FOR 5-MONTH TRANSITION PERIOD ENDED DECEMBER 31, 2017​ Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-08T21:12:00.000+02:00",
    "crawled": "2018-02-09T16:42:01.008+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "opiant",
        "pharmaceutical",
        "inc",
        "opiant",
        "pharmaceutical",
        "record",
        "approximately",
        "million",
        "royalty",
        "milestone",
        "payment",
        "related",
        "sale",
        "nasal",
        "spray",
        "opioid",
        "overdose",
        "opiant",
        "pharmaceutical",
        "record",
        "total",
        "million",
        "royalty",
        "milestone",
        "payment",
        "transition",
        "period",
        "ended",
        "december",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}